概要：①多伦多枪击案14人受伤1人死亡②特朗普和伊朗总统推特上互相威胁③英国外交大臣警告欧盟谈判员④治疗疟疾的新药物被美国监管部门通过

↓==========【原速】新闻视频=========↓

↓========【0.9x倍速】新闻视频=======↓

↓========【0.8x倍速】新闻视频=======↓

↓========【0.7x倍速】新闻视频=======↓

==========↓摊开来的概要↓==========

①多伦多枪击案14人受伤1人死亡

（早报讯）根据加拿大多伦多警方披露的最新消息，当地枪击案已经导致一人死亡和14人受伤，包括一名女孩童。此外，枪手已经自尽。

多伦多警察局局长桑德斯对记者说，女童情况危急。

警方说，枪手使用的是一把手-枪。早前的报道说，有九人被打伤。

当地媒体报道，事件发生在星期天晚上约10时，地点在多伦多市内的希腊城社区。目击者说，他们听到25声枪响。




②特朗普和伊朗总统推特上互相威胁

在伊朗总统鲁哈尼警告美国“切勿玩弄狮子尾巴”后，美国总统特朗普“愤怒”回应：永远不要再威胁美国！小心点！

特朗普22日在社交媒体推特用大写字母写道：“给伊朗总统鲁哈尼：永远不要再威胁美国，否则你将遭到历史上前所未有的后果。我们不再是一个会支持你疯狂暴力及死亡言辞的国家。小心点！”

22日，伊朗总统鲁哈尼在一场外交官聚会上称，特朗普对伊采取敌对政策，“美国应该知道，与伊朗的战争是一切战争之母。”他还警告特朗普“切勿玩弄狮子的尾巴，这只会带来后悔”。




③英国外交大臣警告欧盟谈判员

英国新上任外交大臣韩特今天表示，随著达成脱欧协议的最后期限越来越近，倘若欧洲联盟（EU）谈判人员一味等待英国让步，恐出现英国脱离欧盟却未达成一纸协议的风险。

韩特（Jeremy Hunt）上任后首次出访来到柏林。他说，德国是「英国在世上关系最密切的友邦之一」，双方同样致力于建立一个以规则为基础的国际秩序。但这一切可能因为混乱脱欧而被打乱。

韩特在和德国外长马斯（Heiko Maas）共同召开的记者会上表示，「提到脱欧，很有可能出现脱欧却未达协议的意外」。支持脱欧的外交大臣强生（Boris Johnson）9日辞职，由韩特接任。

距英国预定脱离欧盟只剩下8个多月的时间，谈判人员对于英国应以何种形式脱离欧盟仍有很深的歧见。

韩特说：「我猜欧盟一定有不少人在想，只要等得够久，英国就会让步。」

他说：「我真正关心的是『混乱脱欧』将改变英国大众对欧洲的态度达一个世代，进而导致关系出现嫌隙，而深具破坏性。」

德国外长马斯说，德国并不希望见到英国失序脱欧。

他说：「我们希望达成协议，而且我们也清楚我们必须采取行动，拉近彼此距离。」不过，马斯也表示，必须维护欧盟的整体利益。




④治疗疟疾的新药物被美国监管部门通过
（无相关中文新闻）

A new drug to treat malaria has been given the green light by authorities in the United States.

The medicine is specifically for the recurring form of malaria - caused by the parasite plasmodium vivax - which makes 8.5 million people ill each year.

This type of malaria is a particular challenge to get rid of as it can remain dormant in the liver for years before reawakening many times.

Scientists have described tafenoquine as a "phenomenal achievement."

Regulators around the world will now look at the drug to see if they can recommend it for their populations.

=======Relapsing illness=======
Recurring malaria is the most common type of malaria outside Sub-Saharan Africa.

Children can be particularly at risk, getting several bouts of malaria from a single bite, missing lots of school and getting weaker each time they get the disease.

And infected people can act as unwitting reservoirs of the disease because when the parasite reawakens in their bodies a mosquito can carry that parasite on to someone else.

This can make it hard to eliminate around the world.

Now the Food and Drug Administration (FDA) in the United States has given the seal of approval to tafenoquine, a drug that can flush the parasite out of its hiding place in the liver and stop people getting it again.

It can be taken alongside another medicine to treat the immediate infection.

There is already a medication that can be used to get rid of malaria hiding in the liver called primaquine.

But unlike the single dose of tafenoquine needed, primaquine often needs to be taken for 14 days.

Some experts are concerned that many people feel better after just a few days and stop taking the pills, allowing the parasite to awaken at a later date.

=======Caution needed=======
The FDA says the drug is effective and approves it for use in the United States but points out that there are important side effects to be aware of.

For example people with an enzyme problem, called G6PD deficiency, should not take the drug as it can cause severe anaemia.

The regulator recommends people are tested for the deficiency for this before it is given - which can pose a problem in poorer areas where malaria is common.

There are also concerns that at higher doses it can be a problem for people with psychiatric illnesses.

But despite these cautions there is hope the drug, together with bed nets and other precautions, will help reduce the amount of vivax malaria in the world.

Prof Ric Price, of Oxford University, told the BBC: "The ability to get rid of the parasite in the liver with a single dose of tafenoquine is a phenomenal achievement and in my mind it represents one of the most significant advances in malaria treatment in the last 60 years."

Meanwhile Dr Hal Barron, president of research and development at GSK, the company that manufactures the drug, said it was a significant milestone for people living with this type of relapsing malaria.

"Together with our partner, Medicines for Malaria Venture, we believe Krintafel will be an important medicine for patients with malaria and contribute to the ongoing effort to eradicate this disease."

Tafenonquine has been in existence since the 1970s but working with Medicines for Malaria, GSK has repurposed the drug so that it can be used to get rid of malaria parasites in the liver.

The next step will be for the drug to be assessed by regulators in countries where this form of malaria is a significant problem.